Key Metrics of Precigen, Inc
Revenue$6.2M▼ 76.9% YoYFY 2023
Operating income−$99.8M
Net profit−$95.9M▼ 438.9% YoY
Shareholders' equity$118M
Market cap$2.3BPGEN · $6.39
Competitors10identified
About Precigen, Inc
Sectors
Company details
- Website
- precigen.com
- Listed
- Nasdaq: PGEN
Operational Areas of Precigen, Inc
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal namePrecigen Inc.
TickerPGEN
ExchangeNasdaq
CountryUnited States
SEC CIK0001356090
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttps://precigen.com
US market & SEC filings
PGEN · Nasdaq · SEC CIK 0001356090
Last price · 25 Oct 2026
$6.39
−3.18%
Market cap$2.3B
P/E—On FY 2023 diluted EPS
Volume6,253,868
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited States
PGEN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeGermantown
GSTIN—
Email—
Websitehttps://precigen.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Precigen, Inc
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
biotechnology
Filings
No filings on record yet.